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IN this work we have focused on the ability of interleukin-1
to induce an acute phase protein response and a de-
granulation of polymorphonuclear leukocytes in vivo. The
capacity of the interleukin-1 receptor antagonist to influ-
ence these events was also investigated. It was shown
that interleukin-1 induced an acute phase protein response
in rats and mice. In rats czz-macroglubolin levels were
increased in plasma after an interleukin-1 injection
whereas zl-inhibitor-3 decreased in plasma. In the mice
plasma amyloid P was increased. The interleukin-1 re-
ceptor antagonist blocked the increase of 0c2-macroglobulin
and plasma amyloid P in a dose dependent way while the
effect on the l-inhibitor-3 decrease was less pronounced.
Interleukin-1 led to polymorphonuclear leukocyte degra-
nulation in vivo as measured by increased cathepsin G
plasma levels. The interleukin-1 receptor antagonist could
influence the early phase of this degranulation.
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Introduction
Different forms of tissue injury cause the host to
react with a uniform acute phase response. This
acute phase response is effected by a variety of
mediators including different cytokines. Among the
cytokines, interleukin-1 (IL-1), interleukin-6 (IL-6)
and turnout necrosis factor 0 (TNF 0) have been
shown to hold central positions in the acute phase
response.
2 Several plasma proteins are increased or
decreased as a part of the acute phase response. This
acute phase protein response differs from species to
species. In humans two proteinase inhibitors,
l-antichymotrypsin and oq-proteinase inhibitor
(czl-antitrypsin), are among the strongest reacting
acute phase proteins. Their main function is to
inhibit polymorphonuclear leukocyte (PMN) cath-
epsin G and elastase, respectively.
In the rat o2-macroglobulin (x2m) is a marked
acute phase protein
4 and in the mouse amyloid P
shows highly increased plasma levels in the acute
phase response. The purpose of the present paper
was to evaluate the effect of the IL-1 receptor
antagonist (IL-lra) on some IL-1 mediated
processes in vivo.
Methods
Rat cathepsin G enzyme-linked immunosorbent assay
(ELISA): Rat PMN cathepsin G was isolated as
described
6 and a monospecific polyclonal rabbit
anti-rat cathepsin G antiserum was produced as
(C) 1992 Rapid Communications of Oxford Ltd
described.
7 An IgG-fraction was prepared on a
Protein G Sepharose 4 Fast Flow (Pharmacia LKB
Biotechnology, S-751 82 Uppsala, Sweden) accord-
ing to the manufacturer’s instruction. The IgG-
fraction was characterized by double diffusion.
8 1%
(w/v) agarose in 0.07 M barbital buffer containing
0.2 M calcium lactate .and 1.0 M NaC1 was cast to
1 mm thickness and incubated for 2 days in a humid
chamber. The gel was washed, dried and stained
with Coomassie. The result is given in Fig. 1.
In the ELISA E.I.A. II Plus Microtitration plates
(Flow Laboratories, McLean, VA 22102, USA)
were used. In the first incubation step 100 #1 of
rabbit anti-rat cathepsin G antibody diluted in
0.05 M carbonic buffer with 0.02% (w/v) NAN3, pH
9.8 was incubated per well overnight at 4C. The
plates were washed with phosphate buffered saline,
containing 0.05% (v/v) Tween 20, pH 7.4,
between each incubation. In the second step 200/1
0.01 M sodium phosphate buffer, with 0.5 M NaC1,
0.1% Tween 20, 0.02% (w/v) NaN3 and 2.0% (w/v)
bovine serum albumin (BSA), pH 7.4 was incubated
at room temperature for 0.5-2 h. In the third step
100/1 standard and plasma samples were incubated
for 2 h at 37C. Diisopropylftuorophosphate (Fluka
Chemie Ag, CH-9470 Buchs, Switzerland) in-
activated rat cathepsin G served as standard.
Standard samples were 0, 1.56, 3.12, 6.25,
12.5 and 25 #g 1-1. Rat plasma was diluted 5, 10
and 20 times routinely. Both standard samples and
plasma samples were diluted in 0.01 M sodium
phosphate buffer, with 0.5 M NaCl, 0.1% (v/v)
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FIG. 1. Double diffusion characterization of rabbit anti-rat cathepsin G
antiserum. Samples were: central basin; rat PMN extract; outer basins,
four basins contained different rabbit anti-rat cathepsin G IgG-fractions,
two basins were empty.
Tween 20, 0.02% (w/v) NaN and 1.0% (w/v) BSA,
pH 7.4. In the fourth step 100 1 biotinylated IgG
fractioned rabbit anti-cathepsin G antibody
10 mg 1-1 was diluted 1/100 in the same buffer as
for samples and incubated for 3 h at 37C. In the
fifth step 100 #1 alkaline phosphatase conjugated
avidin (Dakopatts, DK-2600, Glostrup, Denmark)
was diluted 1/500 in 0.01 M phosphate buffer, with
0.01% (v/v) Tween and 0.02% NAN3, pH 7.4 and
incubated at room temperature for 0.5 h. Finally
100 #1 substrate solution [3.8 mM p-nitrophenyl
phosphate (Sigma) in 9.7% (v/v) diethanolami-
ne/HC1 buffer containing 0.5 mM eagle, pH 9.8]
was added and incubated at room temperature. The
absorbance at 405 nm was read in a Titertek
Multiscan spectrophotometer. Standard curve and
sample values were calculated by a Titersoft ELISA
personel computer program (Flow Laboratories,
Rickmansworth, WD3 1PQ, UK).
Antisera: Rabbit anti-rat 02M and rabbit anti-rat
inhibitor-3 (0113) were prepared as described9’1 and
rabbit anti-mouse amyloid P was obtained from
Synergen Inc. CO 80301, USA. The different
proteins were measured by electroimmunoassay.
11
Animal experiments: Male Wistar rats (Mollegaard
Avelslaboratorium A/S, DK-4623 Skensved, Den-
mark) weighing 275-325 g were used. The animals
were conscious during the whole experimental time
and had free access to water and standard food
pellets. Recombinant human IL-lfl was prepared by
recombinant DNA technology in E. coli (Synergen
Inc.). In the 48 h experiments 0.5 #g or 5 #g IL-1
in 1 ml phosphate buffered saline was given as a
single intraperitoneal (i.p.) injection at 0 h. One
group that received 5#g IL-1 was given a
subsequent single i.p injection of 5 mg recombinant
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human IL-1 receptor antagonist (IL-lra) in
phosphate buffered saline at Oh. 1L-lra was
prepared by recombinant DNA technology in E.
coli (Synergen Inc.). Blood samples of approx-
imately 0.5 ml were taken from the tail into tubes
containing EDTA. Plasma was immediately pre-
pared and frozen at -70C. Samples were taken;
0, 12, 24, 36 and 48 h.
In the 12h experiments 5g IL-1 in 1 ml
phosphate buffered saline was given as a single i.p
injection at 0 h. After the IL-1 injection 5 or 25 mg
IL-lra in 1 ml phosphate buffered saline was given
as a subsequent single i.p. injection. One group did
not receive any IL-lra. Blood samples of
approximately 0.5 ml were taken from the tail into
tubes containing EDTA. Plasma was immediately
prepared and frozen at -70C. Samples were
taken at 0, 1, 3, 6 and 12 h.
To study plasma amyloid P in mice, Balb/c strain
(Mollegaard Avelslaboratorium A/S) was used.
Four different groups with five animals in each
received 0.5 #g IL-1 in 100 #1 phosphate buffered
saline i.p. as a single injection. Immediately after
the injection of IL-1, 0, 0.5, 5 or 10 mg IL-lra in
100 #1 phosphate buffer was given in a single
i.p. injection. At 0 and 20 h blood samples were
collected from the tails. EDTA plasma was
prepared and frozen at -70C until analysed.
During the experimental time the animals had free
access to water and standard food pellets.
The animal experiments were sanctioned by the
local ethical committee for animal experiments.
Statistical methods: Student’s t-test (paired groups,
two tailed) was used to test whether and when
groups treated with the IL-lra were different from
corresponding control, p < 0.05 was regarded as
statistically significant.
Results
Rat cathepsin G ELISA: Precision as inter-assay
coefficient of variation for a plasma standard
(n 16) and intra-assay coefficient of variation for
a plasma standard (n--20) was 10% and 7%,
respectively. The sensitivity was 1.5/.tg 1-1.12
Normal rat plasma concentration was less than
1.5g 1-1. When diisopropylfluorophosphate in-
activated cathepsin G was added to normal rat
plasma 90% of the added amount could be measured
with the assay. Dilution-curves of standard samples
and plasma samples with. increased levels were
parallel.
Cathepsin G in IL-1 stimulated rats: The animals did not
show any outer signs of discomfort during the
whole experimental time. Plasma levels of cathepsin
G were increased 1 h after injection of IL-1. Rats
injected with 25 mg IL-lra did not show increasedIL-lra influence on IL-1 efects
90-
6o
3o
0 6 12
Time (h)
10
6 12
Time (h)
b)
60-
3O
2
Time (h)
FIG. 2. (a) Plasma cathepsin G in rats stimulated with 5#g IL-1 in a
single i.p. injection at 0 h. One group (0--0) only received IL-1 and
two groups also received 5mg IL-lra (O--C)) and 25mg IL-lra
(/--/), respectively. IL-lra was administered as a single injection i.p.
at time point 0. Results are given as plasma cathepsin G #g 1-1
(mean _
SE mean of six rats). indicates p < 0.05 compared to untreated
rats. (b) Plasma cathepsin G in rats stimulated with 0.5 #g (--.) or
5 #g (O--) IL-1 by an i.p. injection. One group stimulated with 5 #g
IL-1 also received 5 mg IL-1 ra (C)--C)) administered by the same route.
Results are given as plasma cathepsin G #g -.1 (mean +_ SE mean of five
rats).
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FIG. 4. Plasma level of ll3 in rats stimulated with 0.5 #g (,--) or 5 #g
(--) IL-1 by an i.p. injection. One group stimulated with 5 #g IL-1
also received 5 mg IL-lra (O--O) administered by the same route.
Results are given as mm precipitate height in electroimmunoassay
(mean +_ SE mean of five rats).
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FIG. 3. (a) Plasma level of 2M in rats stimulated with 5 #g (--O) IL-1
by an i.p. injection. Two groups also received 5 mg IL-1 ra (O--O) and
25 mg IL-lra (/k--/k), respectively, administered by the same route.
Results are given as mm precipitate height in electroimmunoassay
(mean ___
SE mean of six rats). indicates p < 0.05 compared to untreated
rats. (b) Plasma level of o2[VI in rats stimulated with 0.5 #g (--) or
5 #g (--) IL-1 by an i.p. injection. One group stimulated with 5 #g
IL-1 also received 5 mg IL-1 ra (O--O) administered by the same route.
Results are given as mm precipitate height in electroimmunoassay
(mean-I-SE mean of five rats). indicates p< 0.05 compared to
untreated rats.
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FIG. 5. Plasma level of amyloid P in mice stimulated with 0.5 #g IL-1
administered by an i.p. injection. After the IL-1 injection the four groups
received different amounts of IL-1 ra; 0 mg IL-1 ra (--), 0.5 mg IL-1 ra
(O--(C)), 5mg IL-lra (I--I--I-q) and 10mg IL-lra (/X--/X). IL-lra was
given by the same route as IL-1. Results are given as mm precipitate
height in electroimmunoassay (mean ___
SE mean of five mice). indicates
p < 0.05 compared to untreated mice.
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plasma levels until 6 h after the injection of IL-1
(Fig. 2a). In rats followed 48 h after the IL-1
injection a peak value was seen after 12 h (Fig. 2b).
Hereafter the plasma level declined. Rats treated
with IL-lra reached the same peak level at 12 h but
showed lower plasma values at 24 and 36h
compared to untreated rats. These differences were
not statistically significant. 02M measured by
electroimmunoassay were detectable in plasma from
rats at 6 h after injection of IL-1 and reached a
maximum level after 24 h. IL-lra administration
caused a dose dependent decrease of this response
(Fig. 3a and 3b).
0113 plasma levels decreased in all rats despite
administration of IL-lra but the decrease in
plasma levels was less pronounced in rats that
received IL-lra (Fig. 4). The lesser decreased
plasma levels seen in IL-lra treated rats were not
statistically significant. Mice stimulated with IL-1
showed an increase in plasma amyloid P levels at
20 h after the stimulation of IL-1. Treatment with
IL-lra could diminish this increase in a dose
dependent manner. Results are shown in Fig. 5.
Discussion
In this study we have focused on the ability of
IL-1 to induce an acute phase protein response and
degranulation of PMNs in vivo. The human IL-lra
potential to influence these events in the rat and
mouse was also investigated.
Tissue damage emerging from inflammation,
neoplasia, trauma, burn injury and operation
trauma induces an acute phase response in the host.
This response includes fever, metabolic changes and
increase or decrease of certain plasma proteins.
Increased protein synthesis during an acute phase
response is due to stimulation of the hepatocytes by
IL-1, TNF and IL-6. The latter cytokine is thought
to play a key role in the human acute phase protein
response.
13 In the rat one of the fastest and strongest
reacting acute phase proteins is 02M.
4 Normally
plasma level is approximately 50g 1-1, which is
just below the detection limit for an electro-
immunoassay. In the acute phase response the
plasma levels may increase to 0.5-5 g 1-1.
After a single injection of IL-1 i.p. a detectable
plasma level of 02M was seen after 6 h and at 24 h
a maximum level was reached. Thereafter the
plasma levels decreased. These increased plasma
levels seen are in agreement with plasma levels and
increased mRNA hepatocyte levels seen in rats
stimulated with turpentine.
4
Rat 0lI is a proteinase inhibitor with a normal
serum concentration of 7-9 g 1-1.14 In an inflam-
matory process the serum level is decreased.
1
Transcription activity in the liver follows this
decrease in serum level. 4 Thus, 01I, is regarded
as a negative acute phase reactant. A single IL-1
injection into rats resulted in a decreased plasma
level reaching a minimum level after 36 h.
In the mouse an i.p. single injection of IL-1 gave
a significant raised plasma level of amyloid P, 20 h
after the injection. This is in agreement with a raised
plasma level seen after subcutaneous turpentine
injection in mice.
IL-lra
15 is a pure receptor antagonist to IL-1. It
has recently been isolated in its native form
16 and
also cloned, lr’18 IL-lra has been shown to influence
inflammatory processes in experimental models.
19- 21
When rats received a single i.p. injection
subsequent to a prior injection of IL-1 it was
possible to totally block the increase of o2M plasma
level. This blockade was seen when a 5 000-fold
molar excess of IL-lra was given and lasted for at
least 12 h. When lesser amounts of IL-lra were
given the increased o2M plasma level could not be
totally blocked. Decreased plasma levels of 0I, after
stimulation by IL-1 were not altered in IL-lra
treated rats.
In mice a single i.p. injection of IL-1 resulted in
increased plasma amyloid P level. Administration
of a single dose IL-lra by the same route diminished
this increase of amyloid P in a dose dependent way.
When a 20 000-fold excess of IL-lra over IL-1 was
given the increase of plasma level was reduced to
35% of the one obtained without IL-lra. The data
presented so far, clearly demonstrates the ability of
IL-lra to compete with IL-1 in binding to the IL-1
receptor in rat and mouse in vivo.
The difference in the capacity of IL-lra to
influence the positive respective the negative acute
phase protein response in IL-1 stimulated animals
illustrate the complexity of the protein synthesis
during the acute phase response. It may suggest an
occurrence of receptor subtypes for IL-1 on
hepatocytes or on cells capable of producing e.g.
IL-6 and TNF.
Human PMNs possess a high affinity receptor for
human recombinant IL-lz to the number of
approximately 700 per cell.
22 IL-lfl and rhlL-lra
have also been shown to bind to this type II IL-1
receptor.
2 In vitro human PMNs have been shown
to degranulate when stimulated by IL-1 purified
from monocytes.
24 However, these results could not
be confirmed when recombinant IL-1 was used as
a stimulating agent.
25 The explanation for the
difference in results may be due to the difficulty in
obtaining absolutely pure IL-1 preparations from
monocyte-cultures. Our results clearly demonstrate
that recombinant IL-1 administered i.p. in the rat
led to a degranulation from PMNs in vivo as
measured by increased cathepsin G plasma level.
The release of cathepsin G by stimulation of IL-1
was dose related. Cathepsin G is a major enzymatic
constituent in PMN,
26 located in the azurophile
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granulas.
27 The highest plasma level was measured
12 h after the i.p. injection of IL-1. Since IL-1 is
capable of inducing production of other inflam-
matory mediators
28 the fact that IL-1 induces PMN
degranulation in vivo but not in vitro may be due to
this mechanism. However, IL-1 may also act
directly on the PMNs as a primer for degranulation.
Recently recombinant IL-1 has been shown to
enhance formyl-methionyl-leucylphenylalanine in-
duced release of myeloperoxidase.
29 Administration
of a 5 000-fold excess of IL-lra over IL-1 blocked
the release of cathepsin G for 3 h. After 12 h the
highest cathepsin G plasma levels were measured,
independently of whether the rats had received
IL-lra or not: These results may be caused by a
subsequent mobilization of PMNs from the bone
marrow.
Recently it has been shown that both PMN
cathepsin G and elastase are capable of degrading
TNF and TNFfl in vitro but not IL-I.
3 IL-1
shows many effects both as a single mediator and
also in concert with other cytokines e.g. TNFo. The
capability of IL-1 to induce degranulation of at least
cathepsin G in vivo may reflect a regulatory
function of PMN proteinases on TNF. In the
bloodstream the proteinases are inactivated by
proteinase inhibitors but locally in tissues they may
be enzymatically active and thus be able to degrade
proteins.
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